Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

513.12
-7.8800-1.51%
Post-market: 513.310.1900+0.04%19:30 EDT
Volume:415.57K
Turnover:215.18M
Market Cap:22.01B
PE:18.36
High:528.02
Open:523.23
Low:512.29
Close:521.00
52wk High:609.35
52wk Low:302.19
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.96
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.44
PE(LYR):18.42

Loading ...

United Therapeutics Chairperson, CEO Martine Rothblatt Disposes of 9,500 Common Shares for $5.01 Million

Reuters
·
Aug 21

United Therapeutics CEO Martine Rothblatt Disposes of 9,500 Shares for $4.79 Million

Reuters
·
Aug 19

United Therapeutics announces full enrollment in TETON-PPF study

TIPRANKS
·
Aug 17

United Therapeutics Seeks FDA Priority Review for Tyvaso Label Expansion in IPF

Reuters
·
Aug 17

United Therapeutics Corporation Announces Full Enrollment of the Teton-Ppf Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 17

United Therapeutics Corporation - Topline Data from Teton-Ppf Study Expected in Second Half of 2027

THOMSON REUTERS
·
Aug 17

United Therapeutics CEO Chair Martine Rothblatt Disposes of 9,500 Shares for $4.81 Million

Reuters
·
Aug 15

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 8,500 Common Shares Worth $4.45 Million

Reuters
·
Aug 13

United Therapeutics CEO Chairperson Martine Rothblatt Disposes of 9,500 Shares Worth $5.03 Million

Reuters
·
Aug 11

aTyr Pharma Q2 Net Loss Narrows

Reuters
·
Aug 08

Inogen Q2 Revenue up Driven by Higher Demand for Portable Oxygen Concentrators

Reuters
·
Aug 07

United Therapeutics CEO Martine Rothblatt Disposes of 9,595 Common Shares Worth $4.98 Million

Reuters
·
Aug 07

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

TIPRANKS
·
Aug 07

United Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 07

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

MT Newswires Live
·
Aug 06

United Therapeutics Corp. : Wells Fargo Cuts Target Price to $700 from $738

THOMSON REUTERS
·
Aug 06

Morgan Stanley Adjusts PT on United Therapeutics to $515 From $516, Maintains Equalweight Rating

MT Newswires Live
·
Aug 06

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

TIPRANKS
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06